Olfactory dysfunction affects 10%–20% of the general population and up to 80% of patients with chronic rhinosinusitis, imposing a substantial clinical and quality-of-life burden. As the critical pathway for odorant delivery to the olfactory epithelium, the olfactory cleft and its local microenvironment are central to peripheral olfactory impairment, yet prior work has focused heavily on central neural pathways without integrating anatomical, immune and microbial interactions.
This review defines three interlinked etiological domains. Anatomical obstruction—from congenital variants, nasal polyps or respiratory epithelial adenomatoid hamartoma—acts as the initiating factor: it impairs mucociliary clearance, creates a stagnant microenvironment and primes the cleft for downstream inflammation and dysbiosis. Type 2 inflammation serves as the core amplifier, with eosinophil-derived mediators directly damaging olfactory sensory neurons while mucosal edema further narrows the cleft, forming a self-reinforcing loop. Microbiota dysbiosis, dominated by
Staphylococcus aureus biofilms and depleted commensal taxa, modulates immune polarization and sustains local inflammation via microbial metabolites.
For diagnosis, the paper outlines a stepwise multi-dimensional strategy combining subjective scales, psychophysical testing, endoscopic scoring, CT/MRI imaging and OC mucus biomarkers, enabling etiological stratification and inflammatory endotype classification.
On treatment, the review evaluates evidence across pharmacological, biologic, surgical and regenerative modalities. Local delivery innovations, including gelatin sponge packing and steroid-eluting stents, improve therapeutic deposition in the deep, narrow cleft. Type 2-targeted biologics such as dupilumab and tezepelumab deliver significant olfactory improvement with high-level evidence. Surgically, OC dilatation addresses congenital stenosis, while OC blocking is proposed for refractory parosmia, reflecting mechanism-based individualized strategies. Regenerative approaches including platelet-rich plasma injection, olfactory training and probiotic irrigation also show promising clinical value.
The authors conclude that this anatomy-centered framework explains the often refractory nature of OC-related olfactory dysfunction and supports multi-node combination therapy. Future multicenter prospective studies and OC-targeted interventions are needed to further validate and refine the model.
The work titled “An Integrated Framework for Olfactory Cleft-Related Olfactory Dysfunction: Anatomy, Immunity, and Microbiota”, was published on
ENT Discovery (published on Sept 30, 2026).
DOI:
10.15302/ENTD.2026.090007